Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment
- PMID: 2582256
- DOI: 10.1056/NEJM198507043130102
Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment
Abstract
Multiple neurotransmitter deficits found in recent autopsy studies of patients with Alzheimer's disease may militate against the success of "simple cholinergic replacement" as treatment. To study acetylcholine synthesis, we measured the incorporation of radiolabeled glucose into the transmitter in temporal-cortex specimens obtained at diagnostic craniotomy in 17 young patients with Alzheimer's disease. Synthesis of acetylcholine was significantly correlated with cognitive impairment. These results are consistent with the view that the deficit in the presynaptic cholinergic system is a relatively early change in the development of the clinical features of the disease. Other alterations in noradrenergic cells, some cortical neurons, postsynaptic cortical receptors, and possibly serotoninergic cells may not be closely associated with Alzheimer's disease.
Similar articles
-
Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models.Neurochem Int. 2005 Apr;46(5):409-22. doi: 10.1016/j.neuint.2004.11.005. Epub 2005 Jan 17. Neurochem Int. 2005. PMID: 15737439
-
Alzheimer's disease: choline acetyltransferase activity in brain tissue from clinical and pathological subgroups.Ann Neurol. 1983 Sep;14(3):284-93. doi: 10.1002/ana.410140306. Ann Neurol. 1983. PMID: 6227276
-
[Pathophysiology of senile dementia].Schweiz Med Wochenschr. 1985 Dec 14;115(50):1803-7. Schweiz Med Wochenschr. 1985. PMID: 2868521 German.
-
[Neurotransmitters in Alzheimer's disease].Ugeskr Laeger. 1990 Jul 23;152(30):2165-8. Ugeskr Laeger. 1990. PMID: 1975961 Review. Danish.
-
The treatment of cognitive impairment in Alzheimer's disease: beyond the cholinergic approach.Psychiatr Clin North Am. 1991 Jun;14(2):461-82. Psychiatr Clin North Am. 1991. PMID: 2062728 Review.
Cited by
-
Terpenoids as potential anti-Alzheimer's disease therapeutics.Molecules. 2012 Mar 19;17(3):3524-38. doi: 10.3390/molecules17033524. Molecules. 2012. PMID: 22430119 Free PMC article. Review.
-
Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.J Neural Transm (Vienna). 1996;103(8-9):1105-16. doi: 10.1007/BF01291795. J Neural Transm (Vienna). 1996. PMID: 9013398 Clinical Trial.
-
People with Down's syndrome can be distinguished on the basis of cholinergic dysfunction.J Neurol Neurosurg Psychiatry. 1989 Nov;52(11):1294-5. doi: 10.1136/jnnp.52.11.1294. J Neurol Neurosurg Psychiatry. 1989. PMID: 2531786 Free PMC article.
-
Loss of muscarinic cholinergic receptors from the temporal cortex of alcohol abusers.Metab Brain Dis. 1989 Jun;4(2):121-41. doi: 10.1007/BF00999390. Metab Brain Dis. 1989. PMID: 2547145
-
Mental status changes induced by eye drops in dementia of the Alzheimer type.J Neurol Neurosurg Psychiatry. 1987 Jan;50(1):113-5. doi: 10.1136/jnnp.50.1.113. J Neurol Neurosurg Psychiatry. 1987. PMID: 3819748 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical